Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label; Disabled scientists are often left out of academia. The NIH can help change that

Taking stock of the drug industry, from the lab to the medicine chest

March 11, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Amanda Andrade-Rhoades/AP STAT+ | Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label The label expansion could boost demand and insurance coverage for Novo Nordisk's popular but expensive obesity drug. By Elaine Chen Opinion: Disabled scientists are often left out of academia. The NIH can help change that Disabled researchers like us offer innovation, problem solving, and insight. But too often, they are left out of academia. By Elizabeth Weaver II and Kiana Jackson STAT+ | U.K. researchers warn about biases in medical devices, health care algorithms A new report warned about the products' biases potentially hurting patients from underrepresented racial and ethnic groups. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser